¼¼°èÀÇ À̸¶Æ¼´Õ(Imatinib) ÀǾàǰ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Á¦Çüº°, ¿ëµµº°, Áö¿ªº° ºÐ¼®(2023-2030³â)
Global Imatinib Drug Market Size study & Forecast, by Drug Formulation by Application Type and Regional Analysis, 2023-2030
»óǰÄÚµå
:
1363809
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2023³â 10¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
À̸¶Æ¼´ÕÀº ƯÁ¤ ¾Ï Ä¡·á¿¡ »ç¿ëµË´Ï´Ù.
À̸¶Æ¼´ÕÀº Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦(TKI)·Î ¾Ë·ÁÁø ¾à¹° °è¿¿¡ ¼ÓÇÕ´Ï´Ù. À̸¶Æ¼´ÕÀº ƯÁ¤ ¾Ï¼¼Æ÷¿¡¼ »ý¼ºµÇ´Â Ƽ·Î½Å Ű³ª¾ÆÁ¦¶ó´Â ºñÁ¤»óÀûÀÎ ´Ü¹éÁúÀ» ƯÀÌÀûÀ¸·Î Ç¥ÀûÈÇÏ¿© ±× Ȱ¼ºÀ» ¾ïÁ¦ÇÕ´Ï´Ù. À̸¶Æ¼´ÕÀº ÁÖ·Î ºñÁ¤»óÀûÀÎ ¹éÇ÷±¸ °úÀ×»ý¼ºÀ» Ư¡À¸·Î ÇÏ´Â Ç÷¾×¾ÏÀÇ ÀÏÁ¾ÀÎ ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML) Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ, ¼ÒȰü¿¡ ¹ß»ýÇÏ´Â Á¾¾çÀÇ ÀÏÁ¾ÀÎ ¼ÒȰü °£ÁúÁ¾¾ç(GIST) Ä¡·á¿¡µµ ó¹æµÇ±âµµ ÇÕ´Ï´Ù. À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀåÀº ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML)°ú ¼ÒȰü °£ÁúÁ¾¾ç(GIST)ÀÇ ¹ß»ý·ü Áõ°¡, Ç¥ÀûÄ¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
À̸¶Æ¼´ÕÀº ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML) Ä¡·á¿¡ Å« ¼º°øÀ» °ÅµÎ¸ç ³ôÀº ¹ÝÀÀ·ü°ú Àå±âÀûÀÎ ¿¹ÈÄ °³¼±À¸·Î À̾îÁ³½À´Ï´Ù. ±¹¸³ÀÇÇеµ¼°ü(National Library of Medicine)¿¡ µû¸£¸é, ¼¼°è ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML) À¯º´·üÀº 2020³â 112,000¸í, 2030³â 144,000¸í, 2040³â 167,000¸í, 2050³â 181,000¸í 167,000¸í, 2050³â¿¡´Â 181,000¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼¼°èÀûÀ¸·Î ¸¸¼º°ñ¼ö¼º¹éÇ÷º´ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í À̸¶Æ¼´Õ ÀǾàǰ °³¹ß°ú °ü·ÃµÈ R&D Ȱµ¿ÀÌ È°¹ßÇØÁö¸é¼ ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª À̸¶Æ¼´Õ ÀǾàǰÀÇ ³ôÀº ºñ¿ë°ú ´ëüǰÀÇ °¡¿ë¼ºÀº 2023-2030³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
À̸¶Æ¼´Õ ¼¼°è ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç, ¾à¹°ÀÇ ½ÅÈï ½ÃÀå °³Ã´, ÀÌ Áö¿ªÀÇ ¾Ï Áúȯ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ 2022³â ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¾Ï ¹ßº´·ü Áõ°¡, ½Å¾à°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ½Å¾à°³¹ßÀ» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.
ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû/¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ȯ°æ°ú ½ÃÀå »óȲ¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇԵ˴ϴÙ.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ¸ñÀû
- ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ´ë»ó³â
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå ¿ªÇÐ
- À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå ¿µÇ⠺м®(2020-2030³â)
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ¹ÙÀ̾îÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷°£ °æÀï °ü°è
- Porter's Five Forces ¿µÇ⠺м®
- PEST ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- COVID-19ÀÇ ¿µÇ⠺м®
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦5Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå : Á¦Çüº°
- ½ÃÀå ÇöȲ
- ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå : Á¦Çüº°, ½ÇÀû-°¡´É¼º ºÐ¼®
- À̸¶Æ¼´Õ ÀǾàǰ ¼¼°è ½ÃÀå, Á¦Çüº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
- À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
Á¦6Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå : ¿ëµµ À¯Çüº°
- ½ÃÀå ÇöȲ
- ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå : ¿ëµµ À¯Çüº°, ½ÇÀû-°¡´É¼º ºÐ¼®
- À̸¶Æ¼´Õ Á¦Á¦ ¼¼°è ½ÃÀå, ¿ëµµ À¯Çüº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
- À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
- Çʶóµ¨ÇÇ¾Æ ¾ç¼º ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´
- È£»ê±¸Áõ´ÙÁõÈıº(HES)
- °ñ¼öÀÌÇü¼ºÁõÈıº(MDS)
- °ñ¼öÁõ½Ä¼º Áúȯ(MPD)
- À§Àå°ü ±âÁúÁ¾¾ç(GIST)
- ±âŸ
Á¦7Àå ¼¼°èÀÇ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå, Áö¿ª ºÐ¼®
- ÁÖ¿ä ±¹°¡
- ÁÖ¿ä ½ÅÈï ±¹°¡
- À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
- ºÏ¹Ì
- ¹Ì±¹
- Á¦Çü ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ¿ëµµ À¯Çü ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ij³ª´Ù
- À¯·´ À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå ÇöȲ
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾çÀ̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå ÇöȲ
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä« À̸¶Æ¼´Õ ÀǾàǰ ½ÃÀå ÇöȲ
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Sun Pharmaceutical Industries Ltd.
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
- Á¦Ç° °³¿ä
- ÃÖ±Ù µ¿Çâ
- Novartis AG
- Dr. Reddy's Laboratories Ltd
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Cipla Inc
- Apotex Inc
- Sanofi S.A
- Glenmark Pharmaceuticals Ltd.
- Dongbao Pharmaceutical Co. Ltd.
Á¦9Àå Á¶»ç °úÁ¤
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
- Á¶»çÀÇ ÀüÁ¦Á¶°Ç
LSH
¿µ¹® ¸ñÂ÷
Imatinib drug is used to treat certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Imatinib specifically targets and inhibits the activity of abnormal proteins called tyrosine kinases, which are produced by specific cancer cells. Imatinib is primarily used for the treatment of chronic myeloid leukemia (CML), a type of blood cancer characterized by the overproduction of abnormal white blood cells. It can also be prescribed for the treatment of gastrointestinal stromal tumors (GISTs), a type of tumor that occurs in the gastrointestinal tract. The Imatinib Drug market is expanding because of factors such as Increasing incidence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) and increase in demand for target drug therapy.
Imatinib has demonstrated remarkable success in the treatment of CML, leading to high response rates and improved long-term outcomes. Thus, Rising prevelance of chronic myeloid leukemia is driving the market growth. According to National Library of Medicine, The prevalence of chronic myeloid leukemia (CML) across the globe is 112,000 in year 2020, and it is projected to increase to 144,000 by year 2030, and 167,000 cased by year 2040 and 181,000 cases by year 2050. The rising prevelance of chronic myeloid leukemia across the globe is driving the market growth. In addition, rise in healthcare expenditure and increasing R&D activities related to imatinib drug development is creating a lucrative opportunity in the market. However, high cost of imatinib drug and availability of substitutes stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Imatinib Drug Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in year 2022 owing to presence of key market players, rising development of drug, rising prevelance of cancer disease in the region. Whereas Asia Pacific is witnessing a significant growth owing to factors such as rising prevelance of cancer in the region, rising investment in drug discovery activities, rising government initiatives for promoting drug development activities.
Major market player included in this report are:
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Dr. Reddy's Laboratories Ltd
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Cipla Inc
- Apotex Inc
- Sanofi S.A
- Glenmark Pharmaceuticals Ltd.
- Dongbao Pharmaceutical Co. Ltd.
Recent Developments in the Market:
- In October 2021, Tenax Therapeutics, Inc. Announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for a novel formulation of imatinib.
Global Imatinib Drug Market Report Scope:
- Historical Data: 2020 - 2021
- Base Year for Estimation: 2022
- Forecast period: 2023-2030
- Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered: Drug Formulation, Application Type, Region
- Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Formulation offerings of key players. The detailed segments and sub-segment of the market are explained below.
By Drug Formulation:
By Application Type:
- Philadelphia Positive Chronic Myeloid Leukemia
- Hyper-Eosinophilic Syndrome (HES)
- Myelodysplastic Syndrome (MDS)
- Myeloproliferative Diseases (MPD)
- Gastrointestinal Stromal Tumors (GIST)
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1. Imatinib Drug Market, by Region, 2020-2030 (USD Billion)
- 1.2.2. Imatinib Drug Market, by Drug Formulation, 2020-2030 (USD Billion)
- 1.2.3. Imatinib Drug Market, by Application Type, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Imatinib Drug Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Industry Evolution
- 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Imatinib Drug Market Dynamics
- 3.1. Imatinib Drug Market Impact Analysis (2020-2030)
- 3.1.1. Market Drivers
- 3.1.1.1. Increasing incidence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs)
- 3.1.1.2. Increase in demand for target drug therapy.
- 3.1.2. Market Challenges
- 3.1.2.1. High Cost of Imatinib Drug
- 3.1.2.2. Availability of substitutes
- 3.1.3. Market Opportunities
- 3.1.3.1. Rise in healthcare expenditure
- 3.1.3.2. Increasing R&D activities related to imatinib.
Chapter 4. Global Imatinib Drug Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Imatinib Drug Market, by Drug Formulation
- 5.1. Market Snapshot
- 5.2. Global Imatinib Drug Market by Drug Formulation, Performance - Potential Analysis
- 5.3. Global Imatinib Drug Market Estimates & Forecasts by Drug Formulation 2020-2030 (USD Billion)
- 5.4. Imatinib Drug Market, Sub Segment Analysis
- 5.4.1. Capsules
- 5.4.2. Tablets
Chapter 6. Global Imatinib Drug Market, by Application Type
- 6.1. Market Snapshot
- 6.2. Global Imatinib Drug Market by Application Type, Performance - Potential Analysis
- 6.3. Global Imatinib Drug Market Estimates & Forecasts by Application Type 2020-2030 (USD Billion)
- 6.4. Imatinib Drug Market, Sub Segment Analysis
- 6.4.1. Philadelphia Positive Chronic Myeloid Leukemia
- 6.4.2. Hyper-Eosinophilic Syndrome (HES)
- 6.4.3. Myelodysplastic Syndrome (MDS)
- 6.4.4. Myeloproliferative Diseases (MPD)
- 6.4.5. Gastrointestinal Stromal Tumors (GIST)
- 6.4.6. Others
Chapter 7. Global Imatinib Drug Market, Regional Analysis
- 7.1. Top Leading Countries
- 7.2. Top Emerging Countries
- 7.3. Imatinib Drug Market, Regional Market Snapshot
- 7.4. North America Imatinib Drug Market
- 7.4.1. U.S. Imatinib Drug Market
- 7.4.1.1. Drug Formulation breakdown estimates & forecasts, 2020-2030
- 7.4.1.2. Application Type breakdown estimates & forecasts, 2020-2030
- 7.4.2. Canada Imatinib Drug Market
- 7.5. Europe Imatinib Drug Market Snapshot
- 7.5.1. U.K. Imatinib Drug Market
- 7.5.2. Germany Imatinib Drug Market
- 7.5.3. France Imatinib Drug Market
- 7.5.4. Spain Imatinib Drug Market
- 7.5.5. Italy Imatinib Drug Market
- 7.5.6. Rest of Europe Imatinib Drug Market
- 7.6. Asia-Pacific Imatinib Drug Market Snapshot
- 7.6.1. China Imatinib Drug Market
- 7.6.2. India Imatinib Drug Market
- 7.6.3. Japan Imatinib Drug Market
- 7.6.4. Australia Imatinib Drug Market
- 7.6.5. South Korea Imatinib Drug Market
- 7.6.6. Rest of Asia Pacific Imatinib Drug Market
- 7.7. Latin America Imatinib Drug Market Snapshot
- 7.7.1. Brazil Imatinib Drug Market
- 7.7.2. Mexico Imatinib Drug Market
- 7.8. Middle East & Africa Imatinib Drug Market
- 7.8.1. Saudi Arabia Imatinib Drug Market
- 7.8.2. South Africa Imatinib Drug Market
- 7.8.3. Rest of Middle East & Africa Imatinib Drug Market
Chapter 8. Competitive Intelligence
- 8.1. Key Company SWOT Analysis
- 8.1.1. Company 1
- 8.1.2. Company 2
- 8.1.3. Company 3
- 8.2. Top Market Strategies
- 8.3. Company Profiles
- 8.3.1. Sun Pharmaceutical Industries Ltd.
- 8.3.1.1. Key Information
- 8.3.1.2. Overview
- 8.3.1.3. Financial (Subject to Data Availability)
- 8.3.1.4. Product Summary
- 8.3.1.5. Recent Developments
- 8.3.2. Novartis AG
- 8.3.3. Dr. Reddy's Laboratories Ltd
- 8.3.4. Teva Pharmaceutical Industries Ltd.
- 8.3.5. Mylan N.V.
- 8.3.6. Cipla Inc
- 8.3.7. Apotex Inc
- 8.3.8. Sanofi S.A
- 8.3.9. Glenmark Pharmaceuticals Ltd.
- 8.3.10. Dongbao Pharmaceutical Co. Ltd.
Chapter 9. Research Process
- 9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes
- 9.3. Research Assumption
°ü·ÃÀÚ·á